This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® Genitourinary Cancers Symposium 2022
Presentations

Enfortumab Vedotin | Urothelial Carcinoma | Abstract #TPS589
Study EV-302: A 2-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (Trial in Progress)

Enfortumab Vedotin | Bladder Cancer | Abstract #TPS587
Study EV-103 Cohort L: Evaluating perioperative enfortumab vedotin monotherapy in cis-ineligible muscle invasive bladder cancer (MIBC) (Trial in Progress)

Enfortumab Vedotin | Solid Tumors | Abstract #568
Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

Urothelial Carcinoma | Abstract #570
Systematic literature review (SLR) and network meta-analysis (NMA) of first-linetherapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC)

Tucatinib | Urothelial Cancer | Abstract #TPS586
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress)

Enfortumab Vedotin | Bladder Cancer | Abstract #435
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible